On November 29, 2022, Cajal Neuroscience Inc., a biotechnology company integrating human genetics, functional genomics, and advanced microscopy to discover novel targets and therapeutics for neurodegeneration, launched with the completion of approximately $96 million in Series A funding. Cajal is uniquely focused on the mechanistic, spatial, and temporal complexity of neurodegeneration, integrating deep expertise in neuroscience, neuroanatomy, and computational biology with state-of-the-art technologies for high-throughput functional validation. The financing was led by The Column Group and Lux Capital, with additional participation from Two Sigma Ventures, Bristol Myers Squibb, Evotec, Alexandria Venture Investments, Dolby Family Ventures, and other investors.

Wilson Sonsini Goodrich & Rosati represented Cajal Neuroscience in the transaction. The corporate team includes Ken Clark, Christina Poulsen, Travis Scheft, Zack Lenox, and Laura Garvey. Marina C. Tsatalis and David Hoffmeister also supported the team in the transaction.

For more information, please see Cajal Neuroscience's press release.